bone morphogenetic protein 8bGenealiases: BMP8 · OP2
Q-omics provides the consensus-scored BMP8B profile across patient tissues and cancer cell-line models. BMP8B expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, BMP8B is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, BMP8B RNA expression shows 18,337 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, KIRC, and THYM as cancer lineages where BMP8B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BMP8B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BMP8B survival associations across molecular data types. BMP8B RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BMP8B RNA expression–survival associations across cancer types. High BMP8B expression shows unfavorable associations in MESO, ACC, LAML, LGG, THCA and BRCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for BMP8B RNA expression.
This table summarizes BMP8B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for BMP8B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BMP8B shows lower tumor expression in THCA and higher tumor expression in KIRC, BLCA, HNSC, LUAD and BRCA. The KIRC box plot shows higher BMP8B RNA expression in tumor versus normal tissue (log2 FC = +1.447, t-test p < 0.001).
This table shows molecular features associated with BMP8B in patient tissues and cancer cell lines. In patient samples, BMP8B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, BMP8B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
